A meta-analysis of the year-round vaccine persistency of trivalent inactivated influenza vaccine among elderly aged 65 years and above
10.19485/j.cnki.issn1007-0931.2017.11.007
- VernacularTitle:65岁及以上老年人接种TIV一年内免疫持久性的Meta分析
- Author:
Yu HU
1
;
Qian LI
;
Ying WANG
;
Ya-Ping CHEN
Author Information
1. 浙江省疾病预防控制中心免疫规划所
- Keywords:
Trivalent inactivated influenza vaccine;
Vaccine persistency;
Meta-analysis
- From:
Journal of Preventive Medicine
2017;29(11):1109-1114,1118
- CountryChina
- Language:Chinese
-
Abstract:
Objective To evaluate the year-round vaccine persistency of trivalent inactivated influenza vaccine (TIV) among elderly aged 65 years and above. Methods Searching "National Center for Biotechnology Information" , "Cochrane Library, CL", "China Biology Medicine disc", "China National Knowledge Infrastructure", "Wanfang Database", the studies of the year-round vaccine persistency of trivalent inactivated influenza vaccine among the elderly aged 65 years and above were included, and meta-analysis were made by Stata 11.0 software. Results A total of 17 studies were included. Compared with the antibody level before immunization, the standard mean differences (SMDs) of geometric mean titer (GMT) was 0.10 (95%CI: -0.12-0.32), 0.57 (95%CI: 0.23-0.91), 0.47 (95%CI:-0.20-1.15) and -0.27 (95%CI: -0.51--0.04) for the total haemagglutination inhibition (HI) antibody, the HI antibody of A/H1N1, the HI antibody of A/H3N2 and the HI antibody of B, respectively, by 360 day. The risk differences (RD) of sero-protection rate (SP) was 0.06 (95%CI: -0.04-0.16), 0.09 (95%CI: -0.15-0.33), -0.08 (95%CI: -0.28-0.13) and 0.00 (95%CI: -0.13 - -0.13) for the total haemagglutination inhibition (HI) antibody, the HI antibody of A/H1N1, the HI antibody of A/H3N2 and the HI antibody of B, respectively, by 360 day. Conclusion The HI antibody responses following TIV vaccination do not reliably persist year-round in the elderly aged 65 years and above . Clinic trials and health economic evaluation studies are needed to assess the feasibility and cost-effectiveness of multiple doses schedule of TIV in elderly.
